Abstract
Currently, schizophrenia, as a serious psychiatric disorder, continues affecting the quality of life in the psychotics. This disease is often debilitating and chronic, showing broad symptoms at one end by hallucinations, delusions, thought disorder and the other end by affective flattening, catatonia, social isolation. In order to combat this disease, many antipsychotic drugs have been developed and introduced into clinical practice in the past half century. However, only a small minority of them can treat effectively schizophrenia without side effects. In view of this situation, high attention has been given to the exploration of desired antipsychotic agents influential especially through the modulation of dopamine and serotonin receptors with substantial strides made in recent years, leading to the discovery of many novel chemical entities with intriguing profiles. In this review, we summarize novel structural antipsychotics in development and discuss the future direction of ideal antipsychotic drug candiates. In particular, the promising atypical antipsychotic profiles of new molecules and the inspirations for their design are highlighted.
Keywords: Arylpiperazines, atypical antipsychotics, butyrophenones, dopamine and serotonin receptors, schizophrenia, tricycles.
Current Drug Targets
Title:Recent Developments in the Discovery of Novel Antipsychotic Agents Modualating Dopamine and Serotonin Receptors
Volume: 14 Issue: 8
Author(s): Xin Li and Shutao Ma
Affiliation:
Keywords: Arylpiperazines, atypical antipsychotics, butyrophenones, dopamine and serotonin receptors, schizophrenia, tricycles.
Abstract: Currently, schizophrenia, as a serious psychiatric disorder, continues affecting the quality of life in the psychotics. This disease is often debilitating and chronic, showing broad symptoms at one end by hallucinations, delusions, thought disorder and the other end by affective flattening, catatonia, social isolation. In order to combat this disease, many antipsychotic drugs have been developed and introduced into clinical practice in the past half century. However, only a small minority of them can treat effectively schizophrenia without side effects. In view of this situation, high attention has been given to the exploration of desired antipsychotic agents influential especially through the modulation of dopamine and serotonin receptors with substantial strides made in recent years, leading to the discovery of many novel chemical entities with intriguing profiles. In this review, we summarize novel structural antipsychotics in development and discuss the future direction of ideal antipsychotic drug candiates. In particular, the promising atypical antipsychotic profiles of new molecules and the inspirations for their design are highlighted.
Export Options
About this article
Cite this article as:
Li Xin and Ma Shutao, Recent Developments in the Discovery of Novel Antipsychotic Agents Modualating Dopamine and Serotonin Receptors, Current Drug Targets 2013; 14 (8) . https://dx.doi.org/10.2174/13894501113149990007
DOI https://dx.doi.org/10.2174/13894501113149990007 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
Therapeutic Chemical and RNA Design with Artificial Intelligence
Computer-Aided Drug Design (CADD) has emerged as a fundamental component of modern drug discovery. Molecular docking facilitates virtual screening on a large scale through structural simulations. However, traditional CADD approaches face significant limitations, as they can only screen known compounds from existing libraries. PubChem, as the most widely used chemical ...read more

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Drugs Used to Treat Parkinsons Disease, Present Status and Future Directions
CNS & Neurological Disorders - Drug Targets New Insight into the Therapeutic Role of 5-HT1A Receptors in Central Nervous System Disorders
Central Nervous System Agents in Medicinal Chemistry Neurobiology of Sleep Disturbances in Neurodegenerative Disorders
Current Pharmaceutical Design On the Pathogenesis and Neuroprotective Treatment of Parkinson Disease: What have we Learned from the Genetic Forms of this Disease?
Current Medicinal Chemistry Incomplete Coverage of Candidate Genes: A Poorly Considered Bias
Current Genomics Ultra-micronized Palmitoylethanolamide: An Efficacious Adjuvant Therapy for Parkinson’s Disease
CNS & Neurological Disorders - Drug Targets Haloperidol Cytotoxicity and Its Relation to Oxidative Stress
Mini-Reviews in Medicinal Chemistry PET Imaging in Parkinsons Disease
Current Medical Imaging Neurological Aspects of Medical Use of Cannabidiol
CNS & Neurological Disorders - Drug Targets Current Options and Future Possibilities for the Treatment of Dyskinesia and Motor Fluctuations in Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Liposomes: Novel Drug Delivery Approach for Targeting Parkinson’s Disease
Current Pharmaceutical Design Therapeutic Strategies in Parkinsons Disease
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Applications of Lentiviral Vectors for Biology and Gene Therapy of Neurological Disorders
Current Gene Therapy L-DOPA and Serotonergic Neurons: Functional Implication and Therapeutic Perspectives in Parkinson's Disease
Central Nervous System Agents in Medicinal Chemistry Bis(thiosemicarbazone) Metal Complexes as Therapeutics for Neurodegenerative Diseases
Current Topics in Medicinal Chemistry Common Neurogenetic Diagnosis and Meso-Limbic Manipulation of Hypodopaminergic Function in Reward Deficiency Syndrome (RDS): Changing the Recovery Landscape
Current Neuropharmacology GPCR Heteromers and their Allosteric Receptor-Receptor Interactions
Current Medicinal Chemistry Possible Neuroprotective Strategies for Huntingtons Disease
Current Neuropharmacology Patent Annotations
Recent Patents on CNS Drug Discovery (Discontinued) Neural Stem Cells Transplanted in a Mouse Model of Parkinson’s Disease Differentiate to Neuronal Phenotypes and Reduce Rotational Deficit
CNS & Neurological Disorders - Drug Targets